Higher incidence of pegfilgrastim-induced bone pain in younger patients receiving myelosuppressive chemotherapy: a real-world experience.
Shinya TsuboiTatsuya HayamaKatsuhiro MiuraAkihiro UchiikeDaisuke TsutsumiTakashi YamauchiYoshihiro HattaSusumu OotsukaPublished in: Journal of pharmaceutical health care and sciences (2023)
Younger age (< 55 years) was significantly associated with a higher risk of PIBP among patients receiving chemotherapy with a ≥ 10% risk of FN. Therefore, oncologists should meticulously formulate management plan for PIBP in younger patients after administering pegfilgrastim.
Keyphrases
- end stage renal disease
- ejection fraction
- chemotherapy induced
- chronic kidney disease
- newly diagnosed
- chronic pain
- locally advanced
- peritoneal dialysis
- prognostic factors
- squamous cell carcinoma
- risk factors
- pain management
- diabetic rats
- high glucose
- patient reported outcomes
- radiation therapy
- drug induced
- soft tissue
- bone regeneration